Evidence map›Paper›PMID 31882598›Full record

ArticleScientific reports2019

Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.

Whitney Rabacal, Finja Schweitzer, Emily Rayens, Rebecca Tarantelli, Patrick Whang, Viviana Cobos Jimenez, Judy A Outwater, Karen A Norris

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Whitney RabacalCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Finja SchweitzerCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Emily RayensCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Rebecca TarantelliCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Patrick WhangCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Viviana Cobos JimenezCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Judy A OutwaterCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia.
Karen A NorrisCenter for Vaccines and Immunology, University of Georgia, Athens, 30602, Georgia. kanorris@uga.edu.
University of Georgia · US

Funding

Immunopathogenesis of HIV-associated pulmonary hypertensionR01HL131449 · NHLBI · UNIVERSITY OF GEORGIA · PI NORRIS, KAREN A · 2016 to 2019
$3.1M
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial HypertensionR01HL138437 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y, NORRIS, KAREN A · 2017 to 2020
$2.4M
NHLBI NIH HHS R01 HL131449NHLBI NIH HHS R01 HL138437
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by pulmonary vascular remodeling, elevated pulmonary arterial pressure, and right heart failure. Human immunodeficiency virus (HIV)-infected individuals have a higher incidence of PAH than the non-HIV infected population and evidence suggests a role for systemic and pulmonary inflammation in the pathogenesis of HIV-associated PAH. Due to their pleiotropic effects, including immune-modulatory and anti-inflammatory effects, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been considered for the treatment of PAH, with conflicting results. The effects of statins on HIV-associated PAH have not been specifically evaluated. We have developed a non-human primate (NHP) model of HIV-associated PAH that closely mimics HIV-PAH using simian immunodeficiency virus (SIV)-infected rhesus macaques (Macaca mulatta). We determined that treatment of healthy macaques with atorvastatin prior to and throughout SIV infection prevented the development of SIV-associated PAH. Additionally, SIV-infected macaques that initiated atorvastatin treatment during the early chronic disease stage had reduced incidence of PAH compared to untreated animals. Statin treatment reduced inflammatory mediators TGF-β, MIP-1α, and TNF-α and the numbers of CD14

Indexed as

AnimalsAtorvastatinDisease Models, AnimalHIVHIV InfectionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMacaca mulattaMacrophages, AlveolarMonocytesPulmonary Arterial HypertensionSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadAtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID31882598
PMCPMC6934837
OpenAlexW2998126452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.